Cargando…

Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain

Background: Chronic back pain due to facet joint syndrome is a common and debilitating condition. Advances in regenerative medicine have shown that autologous unmodified adipose tissue-derived regenerative cells (ADRC) provide several beneficial effects. These regenerative cells can differentiate in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothoerl, Ralf, Tomelden, Junee, Alt, Eckhard Udo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058908/
https://www.ncbi.nlm.nih.gov/pubmed/36983621
http://dx.doi.org/10.3390/jpm13030436
_version_ 1785016748073811968
author Rothoerl, Ralf
Tomelden, Junee
Alt, Eckhard Udo
author_facet Rothoerl, Ralf
Tomelden, Junee
Alt, Eckhard Udo
author_sort Rothoerl, Ralf
collection PubMed
description Background: Chronic back pain due to facet joint syndrome is a common and debilitating condition. Advances in regenerative medicine have shown that autologous unmodified adipose tissue-derived regenerative cells (ADRC) provide several beneficial effects. These regenerative cells can differentiate into various tissues and exhibit a strong anti-inflammatory potential. ADRCs can be obtained from a small amount of fatty tissue derived from the patient’s abdominal fat. Methods: We report long-term results of 37 patients (age 31–78 years, mean 62.5) suffering from “Facet Joint Syndrome” The pathology was confirmed by clinical, radiological examinations and fluoroscopically guided test injections. Then, liposuction was performed. An amount of 50–100 cc of fat was harvested. To recover stem cells from adipose tissue, we use the CE-certified Transpose RT™ system from InGeneron GmbH. The cells were then injected under fluoroscopic control in the periarticular fat. Follow-up examinations were performed at 1 week, 1 year, and 5 years. Results: Every patient reported improved VAS pain at any follow-up (1 week, 1 year, and 5 years) with ADRCs compared to the baseline. Conclusions: Our observational data indicate that facet joint syndrome patients treated with unmodified adipose tissue-derived regenerative cells experience improved the quality of life in the long term.
format Online
Article
Text
id pubmed-10058908
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100589082023-03-30 Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain Rothoerl, Ralf Tomelden, Junee Alt, Eckhard Udo J Pers Med Article Background: Chronic back pain due to facet joint syndrome is a common and debilitating condition. Advances in regenerative medicine have shown that autologous unmodified adipose tissue-derived regenerative cells (ADRC) provide several beneficial effects. These regenerative cells can differentiate into various tissues and exhibit a strong anti-inflammatory potential. ADRCs can be obtained from a small amount of fatty tissue derived from the patient’s abdominal fat. Methods: We report long-term results of 37 patients (age 31–78 years, mean 62.5) suffering from “Facet Joint Syndrome” The pathology was confirmed by clinical, radiological examinations and fluoroscopically guided test injections. Then, liposuction was performed. An amount of 50–100 cc of fat was harvested. To recover stem cells from adipose tissue, we use the CE-certified Transpose RT™ system from InGeneron GmbH. The cells were then injected under fluoroscopic control in the periarticular fat. Follow-up examinations were performed at 1 week, 1 year, and 5 years. Results: Every patient reported improved VAS pain at any follow-up (1 week, 1 year, and 5 years) with ADRCs compared to the baseline. Conclusions: Our observational data indicate that facet joint syndrome patients treated with unmodified adipose tissue-derived regenerative cells experience improved the quality of life in the long term. MDPI 2023-02-28 /pmc/articles/PMC10058908/ /pubmed/36983621 http://dx.doi.org/10.3390/jpm13030436 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rothoerl, Ralf
Tomelden, Junee
Alt, Eckhard Udo
Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
title Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
title_full Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
title_fullStr Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
title_full_unstemmed Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
title_short Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
title_sort safety and efficacy of autologous stem cell treatment for facetogenic chronic back pain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058908/
https://www.ncbi.nlm.nih.gov/pubmed/36983621
http://dx.doi.org/10.3390/jpm13030436
work_keys_str_mv AT rothoerlralf safetyandefficacyofautologousstemcelltreatmentforfacetogenicchronicbackpain
AT tomeldenjunee safetyandefficacyofautologousstemcelltreatmentforfacetogenicchronicbackpain
AT alteckhardudo safetyandefficacyofautologousstemcelltreatmentforfacetogenicchronicbackpain